Delivery Order SPE2DB22D2005-SPE2DB26FJEC9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a $1,711.16 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed-price contract represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,223.86 under a firm fixed price contract. The delivery order, which is a child contract under a larger vehicle, specifies a completion date of September 23, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. This award was not designated as a set-aside and was competitively awarded,...
- The Defense Logistics Agency awarded a $3,226.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This non-set-aside, competitively awarded contract was executed on October 20, 2025, with an ultimate completion date of October 21, 2025, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $2,440.29 with a firm fixed price. This is a non-set-aside, competitively awarded delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,914.68 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJEC9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,078.57 with a firm fixed price structure. This is a competitively awarded, non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. This award is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of pharmaceutical products and medical supplies serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's established track record of competitively awarded delivery orders demonstrates its capability to meet federal procurement requirements across multiple therapeutic domains and supply categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/21/25 |